nodes	percent_of_prediction	percent_of_DWPC	metapath
Amsacrine—TOP2A—Epirubicin—thyroid cancer	0.35	0.527	CbGbCtD
Amsacrine—TOP2A—Doxorubicin—thyroid cancer	0.186	0.28	CbGbCtD
Amsacrine—ABCB1—Sorafenib—thyroid cancer	0.041	0.0618	CbGbCtD
Amsacrine—CYP2D6—Sorafenib—thyroid cancer	0.0387	0.0582	CbGbCtD
Amsacrine—ABCB1—Doxorubicin—thyroid cancer	0.0249	0.0375	CbGbCtD
Amsacrine—CYP2D6—Doxorubicin—thyroid cancer	0.0235	0.0353	CbGbCtD
Amsacrine—NCOA3—Androgen receptor signaling pathway—NCOA4—thyroid cancer	0.00706	0.104	CbGpPWpGaD
Amsacrine—NCOA3—neck—thyroid cancer	0.00609	0.217	CbGeAlD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.00489	0.0721	CbGpPWpGaD
Amsacrine—NCOA3—saliva-secreting gland—thyroid cancer	0.00475	0.169	CbGeAlD
Amsacrine—NCOA3—Retinoic acid receptors-mediated signaling—CDK1—thyroid cancer	0.00376	0.0555	CbGpPWpGaD
Amsacrine—NCOA3—trachea—thyroid cancer	0.00367	0.131	CbGeAlD
Amsacrine—NCOA3—Retinoic acid receptors-mediated signaling—RXRA—thyroid cancer	0.00349	0.0515	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—NDUFA13—thyroid cancer	0.00331	0.0489	CbGpPWpGaD
Amsacrine—NCOA3—thyroid gland—thyroid cancer	0.0029	0.103	CbGeAlD
Amsacrine—NCOA3—head—thyroid cancer	0.00257	0.0916	CbGeAlD
Amsacrine—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TCF7L1—thyroid cancer	0.00232	0.0343	CbGpPWpGaD
Amsacrine—TOP2A—G0 and Early G1—CDK1—thyroid cancer	0.00191	0.0282	CbGpPWpGaD
Amsacrine—NCOA3—Idarubicin—Epirubicin—thyroid cancer	0.00187	0.221	CbGdCrCtD
Amsacrine—NCOA3—lymph node—thyroid cancer	0.0018	0.0642	CbGeAlD
Amsacrine—NCOA3—Idarubicin—Doxorubicin—thyroid cancer	0.00173	0.205	CbGdCrCtD
Amsacrine—TOP2A—thyroid gland—thyroid cancer	0.0017	0.0606	CbGeAlD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—RXRA—thyroid cancer	0.00164	0.0243	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.00152	0.0225	CbGpPWpGaD
Amsacrine—TOP2A—Erlotinib—Vandetanib—thyroid cancer	0.00152	0.179	CbGdCrCtD
Amsacrine—KCNH2—Hematopoietic Stem Cell Differentiation—EPO—thyroid cancer	0.00147	0.0216	CbGpPWpGaD
Amsacrine—NCOA3—PPARA activates gene expression—RXRA—thyroid cancer	0.00124	0.0182	CbGpPWpGaD
Amsacrine—NCOA3—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.00121	0.0178	CbGpPWpGaD
Amsacrine—Gingival bleeding—Epirubicin—thyroid cancer	0.00113	0.00488	CcSEcCtD
Amsacrine—Malnutrition—Vandetanib—thyroid cancer	0.00112	0.00486	CcSEcCtD
Amsacrine—Dysphagia—Sorafenib—thyroid cancer	0.00109	0.0047	CcSEcCtD
Amsacrine—Mucosal inflammation—Doxorubicin—thyroid cancer	0.00107	0.00463	CcSEcCtD
Amsacrine—Febrile neutropenia—Epirubicin—thyroid cancer	0.00107	0.0046	CcSEcCtD
Amsacrine—Vision blurred—Vandetanib—thyroid cancer	0.00106	0.00458	CcSEcCtD
Amsacrine—TOP2A—lymph node—thyroid cancer	0.00106	0.0376	CbGeAlD
Amsacrine—Gingival bleeding—Doxorubicin—thyroid cancer	0.00104	0.00452	CcSEcCtD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—PPARG—thyroid cancer	0.00104	0.0153	CbGpPWpGaD
Amsacrine—Hypomagnesaemia—Epirubicin—thyroid cancer	0.00101	0.00436	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—RET—thyroid cancer	0.001	0.0148	CbGpPWpGaD
Amsacrine—TOP2A—Afatinib—Vandetanib—thyroid cancer	0.000992	0.117	CbGdCrCtD
Amsacrine—Febrile neutropenia—Doxorubicin—thyroid cancer	0.000986	0.00426	CcSEcCtD
Amsacrine—Weight decreased—Sorafenib—thyroid cancer	0.000984	0.00425	CcSEcCtD
Amsacrine—Convulsion—Vandetanib—thyroid cancer	0.000974	0.00421	CcSEcCtD
Amsacrine—Infestation NOS—Sorafenib—thyroid cancer	0.00097	0.00419	CcSEcCtD
Amsacrine—Infestation—Sorafenib—thyroid cancer	0.00097	0.00419	CcSEcCtD
Amsacrine—Renal failure—Sorafenib—thyroid cancer	0.000953	0.00412	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00095	0.00411	CcSEcCtD
Amsacrine—Bone marrow depression—Epirubicin—thyroid cancer	0.000949	0.0041	CcSEcCtD
Amsacrine—Stomatitis—Sorafenib—thyroid cancer	0.000945	0.00409	CcSEcCtD
Amsacrine—Jaundice—Sorafenib—thyroid cancer	0.000945	0.00409	CcSEcCtD
Amsacrine—Hypomagnesaemia—Doxorubicin—thyroid cancer	0.000933	0.00403	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.000931	0.0137	CbGpPWpGaD
Amsacrine—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—NRG1—thyroid cancer	0.000925	0.0136	CbGpPWpGaD
Amsacrine—Haematemesis—Epirubicin—thyroid cancer	0.000922	0.00399	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000919	0.0136	CbGpPWpGaD
Amsacrine—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000917	0.00397	CcSEcCtD
Amsacrine—Infection—Vandetanib—thyroid cancer	0.000911	0.00394	CcSEcCtD
Amsacrine—Thrombocytopenia—Vandetanib—thyroid cancer	0.000898	0.00388	CcSEcCtD
Amsacrine—Skin disorder—Vandetanib—thyroid cancer	0.000891	0.00385	CcSEcCtD
Amsacrine—Bone marrow depression—Doxorubicin—thyroid cancer	0.000878	0.0038	CcSEcCtD
Amsacrine—Haemoglobin—Sorafenib—thyroid cancer	0.000875	0.00378	CcSEcCtD
Amsacrine—NCOA3—Retinoic acid receptors-mediated signaling—AKT1—thyroid cancer	0.000872	0.0129	CbGpPWpGaD
Amsacrine—Haemorrhage—Sorafenib—thyroid cancer	0.000871	0.00376	CcSEcCtD
Amsacrine—TOP2A—Gefitinib—Vandetanib—thyroid cancer	0.000867	0.102	CbGdCrCtD
Amsacrine—Ventricular arrhythmia—Epirubicin—thyroid cancer	0.000866	0.00374	CcSEcCtD
Amsacrine—Urinary tract disorder—Sorafenib—thyroid cancer	0.00086	0.00372	CcSEcCtD
Amsacrine—Connective tissue disorder—Sorafenib—thyroid cancer	0.000856	0.0037	CcSEcCtD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—CCND1—thyroid cancer	0.000855	0.0126	CbGpPWpGaD
Amsacrine—Urethral disorder—Sorafenib—thyroid cancer	0.000854	0.00369	CcSEcCtD
Amsacrine—Haematemesis—Doxorubicin—thyroid cancer	0.000853	0.00369	CcSEcCtD
Amsacrine—KCNH2—head—thyroid cancer	0.000846	0.0301	CbGeAlD
Amsacrine—NCOA3—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000833	0.0123	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—NKX2-1—thyroid cancer	0.000825	0.0122	CbGpPWpGaD
Amsacrine—Paraesthesia—Vandetanib—thyroid cancer	0.000823	0.00356	CcSEcCtD
Amsacrine—Dyspnoea—Vandetanib—thyroid cancer	0.000818	0.00353	CcSEcCtD
Amsacrine—Gingivitis—Epirubicin—thyroid cancer	0.000816	0.00353	CcSEcCtD
Amsacrine—Necrosis—Epirubicin—thyroid cancer	0.000816	0.00353	CcSEcCtD
Amsacrine—Cardiac disorder—Sorafenib—thyroid cancer	0.000808	0.00349	CcSEcCtD
Amsacrine—Ventricular arrhythmia—Doxorubicin—thyroid cancer	0.000801	0.00346	CcSEcCtD
Amsacrine—Decreased appetite—Vandetanib—thyroid cancer	0.000797	0.00345	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000792	0.00342	CcSEcCtD
Amsacrine—Fatigue—Vandetanib—thyroid cancer	0.000791	0.00342	CcSEcCtD
Amsacrine—Angiopathy—Sorafenib—thyroid cancer	0.00079	0.00341	CcSEcCtD
Amsacrine—Mediastinal disorder—Sorafenib—thyroid cancer	0.000785	0.00339	CcSEcCtD
Amsacrine—Pain—Vandetanib—thyroid cancer	0.000784	0.00339	CcSEcCtD
Amsacrine—NCOA3—PPARA activates gene expression—PPARG—thyroid cancer	0.00078	0.0115	CbGpPWpGaD
Amsacrine—Arrhythmia—Sorafenib—thyroid cancer	0.000778	0.00336	CcSEcCtD
Amsacrine—Alopecia—Sorafenib—thyroid cancer	0.000769	0.00333	CcSEcCtD
Amsacrine—NCOA3—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000764	0.0113	CbGpPWpGaD
Amsacrine—Mental disorder—Sorafenib—thyroid cancer	0.000763	0.0033	CcSEcCtD
Amsacrine—Malnutrition—Sorafenib—thyroid cancer	0.000758	0.00328	CcSEcCtD
Amsacrine—Gingivitis—Doxorubicin—thyroid cancer	0.000755	0.00327	CcSEcCtD
Amsacrine—Necrosis—Doxorubicin—thyroid cancer	0.000755	0.00327	CcSEcCtD
Amsacrine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00075	0.00324	CcSEcCtD
Amsacrine—Extravasation—Epirubicin—thyroid cancer	0.000734	0.00317	CcSEcCtD
Amsacrine—Body temperature increased—Vandetanib—thyroid cancer	0.000725	0.00313	CcSEcCtD
Amsacrine—Abdominal pain—Vandetanib—thyroid cancer	0.000725	0.00313	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.000704	0.0104	CbGpPWpGaD
Amsacrine—Anaemia—Sorafenib—thyroid cancer	0.000701	0.00303	CcSEcCtD
Amsacrine—Hyperuricaemia—Epirubicin—thyroid cancer	0.000691	0.00299	CcSEcCtD
Amsacrine—Extravasation—Doxorubicin—thyroid cancer	0.00068	0.00294	CcSEcCtD
Amsacrine—Leukopenia—Sorafenib—thyroid cancer	0.000679	0.00293	CcSEcCtD
Amsacrine—Blood bilirubin increased—Epirubicin—thyroid cancer	0.000678	0.00293	CcSEcCtD
Amsacrine—Creatinine increased—Epirubicin—thyroid cancer	0.000673	0.00291	CcSEcCtD
Amsacrine—Inflammation—Epirubicin—thyroid cancer	0.000661	0.00286	CcSEcCtD
Amsacrine—Asthenia—Vandetanib—thyroid cancer	0.000658	0.00284	CcSEcCtD
Amsacrine—NCOA3—Androgen receptor signaling pathway—CCND1—thyroid cancer	0.000657	0.00969	CbGpPWpGaD
Amsacrine—Blood uric acid increased—Epirubicin—thyroid cancer	0.000653	0.00282	CcSEcCtD
Amsacrine—Musculoskeletal pain—Epirubicin—thyroid cancer	0.000649	0.0028	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000641	0.00277	CcSEcCtD
Amsacrine—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.000641	0.00277	CcSEcCtD
Amsacrine—Hyperuricaemia—Doxorubicin—thyroid cancer	0.000639	0.00276	CcSEcCtD
Amsacrine—Injection site reaction—Epirubicin—thyroid cancer	0.000637	0.00275	CcSEcCtD
Amsacrine—NCOA3—Metabolism—MINPP1—thyroid cancer	0.000635	0.00937	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—PTEN—thyroid cancer	0.000634	0.00936	CbGpPWpGaD
Amsacrine—Diarrhoea—Vandetanib—thyroid cancer	0.000627	0.00271	CcSEcCtD
Amsacrine—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.000627	0.00271	CcSEcCtD
Amsacrine—Creatinine increased—Doxorubicin—thyroid cancer	0.000623	0.00269	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000619	0.00913	CbGpPWpGaD
Amsacrine—Infection—Sorafenib—thyroid cancer	0.000615	0.00266	CcSEcCtD
Amsacrine—Inflammation—Doxorubicin—thyroid cancer	0.000611	0.00264	CcSEcCtD
Amsacrine—Dizziness—Vandetanib—thyroid cancer	0.000606	0.00262	CcSEcCtD
Amsacrine—Thrombocytopenia—Sorafenib—thyroid cancer	0.000606	0.00262	CcSEcCtD
Amsacrine—Blood urea increased—Epirubicin—thyroid cancer	0.000605	0.00261	CcSEcCtD
Amsacrine—Blood uric acid increased—Doxorubicin—thyroid cancer	0.000604	0.00261	CcSEcCtD
Amsacrine—Aplastic anaemia—Epirubicin—thyroid cancer	0.000602	0.0026	CcSEcCtD
Amsacrine—Skin disorder—Sorafenib—thyroid cancer	0.000601	0.0026	CcSEcCtD
Amsacrine—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.0006	0.00259	CcSEcCtD
Amsacrine—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.000593	0.00256	CcSEcCtD
Amsacrine—KCNH2—lymph node—thyroid cancer	0.000592	0.0211	CbGeAlD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.00059	0.0087	CbGpPWpGaD
Amsacrine—Anorexia—Sorafenib—thyroid cancer	0.00059	0.00255	CcSEcCtD
Amsacrine—Injection site reaction—Doxorubicin—thyroid cancer	0.000589	0.00255	CcSEcCtD
Amsacrine—Vomiting—Vandetanib—thyroid cancer	0.000583	0.00252	CcSEcCtD
Amsacrine—Rash—Vandetanib—thyroid cancer	0.000578	0.0025	CcSEcCtD
Amsacrine—Dermatitis—Vandetanib—thyroid cancer	0.000578	0.0025	CcSEcCtD
Amsacrine—Headache—Vandetanib—thyroid cancer	0.000575	0.00248	CcSEcCtD
Amsacrine—Blood urea increased—Doxorubicin—thyroid cancer	0.00056	0.00242	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—BRAF—thyroid cancer	0.000558	0.00822	CbGpPWpGaD
Amsacrine—Aplastic anaemia—Doxorubicin—thyroid cancer	0.000557	0.00241	CcSEcCtD
Amsacrine—Sepsis—Epirubicin—thyroid cancer	0.000556	0.0024	CcSEcCtD
Amsacrine—Dyspnoea—Sorafenib—thyroid cancer	0.000552	0.00238	CcSEcCtD
Amsacrine—Nausea—Vandetanib—thyroid cancer	0.000545	0.00235	CcSEcCtD
Amsacrine—Phlebitis—Epirubicin—thyroid cancer	0.00054	0.00233	CcSEcCtD
Amsacrine—NCOA3—Metabolism—NDUFA13—thyroid cancer	0.00054	0.00796	CbGpPWpGaD
Amsacrine—Decreased appetite—Sorafenib—thyroid cancer	0.000538	0.00232	CcSEcCtD
Amsacrine—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000535	0.00231	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000534	0.00231	CcSEcCtD
Amsacrine—Fatigue—Sorafenib—thyroid cancer	0.000533	0.00231	CcSEcCtD
Amsacrine—Pain—Sorafenib—thyroid cancer	0.000529	0.00229	CcSEcCtD
Amsacrine—ABCB1—trachea—thyroid cancer	0.000529	0.0188	CbGeAlD
Amsacrine—NCOA3—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000526	0.00776	CbGpPWpGaD
Amsacrine—Vascular purpura—Epirubicin—thyroid cancer	0.00052	0.00225	CcSEcCtD
Amsacrine—Hepatic failure—Epirubicin—thyroid cancer	0.000518	0.00224	CcSEcCtD
Amsacrine—CYP2D6—head—thyroid cancer	0.000516	0.0184	CbGeAlD
Amsacrine—Sepsis—Doxorubicin—thyroid cancer	0.000515	0.00222	CcSEcCtD
Amsacrine—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000513	0.00222	CcSEcCtD
Amsacrine—NCOA3—Metabolism—CHST14—thyroid cancer	0.000508	0.00749	CbGpPWpGaD
Amsacrine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000506	0.00219	CcSEcCtD
Amsacrine—Phlebitis—Doxorubicin—thyroid cancer	0.0005	0.00216	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.000495	0.00731	CbGpPWpGaD
Amsacrine—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000495	0.00214	CcSEcCtD
Amsacrine—Urticaria—Sorafenib—thyroid cancer	0.000491	0.00212	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000489	0.00722	CbGpPWpGaD
Amsacrine—Body temperature increased—Sorafenib—thyroid cancer	0.000489	0.00211	CcSEcCtD
Amsacrine—Abdominal pain—Sorafenib—thyroid cancer	0.000489	0.00211	CcSEcCtD
Amsacrine—Purpura—Epirubicin—thyroid cancer	0.000483	0.00209	CcSEcCtD
Amsacrine—Vascular purpura—Doxorubicin—thyroid cancer	0.000481	0.00208	CcSEcCtD
Amsacrine—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000479	0.00707	CbGpPWpGaD
Amsacrine—Hepatic failure—Doxorubicin—thyroid cancer	0.000479	0.00207	CcSEcCtD
Amsacrine—Lethargy—Epirubicin—thyroid cancer	0.000475	0.00205	CcSEcCtD
Amsacrine—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000475	0.00205	CcSEcCtD
Amsacrine—Affect lability—Epirubicin—thyroid cancer	0.000458	0.00198	CcSEcCtD
Amsacrine—Hypersensitivity—Sorafenib—thyroid cancer	0.000456	0.00197	CcSEcCtD
Amsacrine—Purpura—Doxorubicin—thyroid cancer	0.000447	0.00193	CcSEcCtD
Amsacrine—Asthenia—Sorafenib—thyroid cancer	0.000444	0.00192	CcSEcCtD
Amsacrine—TOP2A—Gastric Cancer Network 2—TP53—thyroid cancer	0.000441	0.00651	CbGpPWpGaD
Amsacrine—Mood swings—Epirubicin—thyroid cancer	0.000441	0.0019	CcSEcCtD
Amsacrine—Lethargy—Doxorubicin—thyroid cancer	0.000439	0.0019	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.000439	0.00648	CbGpPWpGaD
Amsacrine—Blood creatinine increased—Epirubicin—thyroid cancer	0.000436	0.00188	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.00043	0.00635	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000427	0.0063	CbGpPWpGaD
Amsacrine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000425	0.00627	CbGpPWpGaD
Amsacrine—Affect lability—Doxorubicin—thyroid cancer	0.000424	0.00183	CcSEcCtD
Amsacrine—Diarrhoea—Sorafenib—thyroid cancer	0.000423	0.00183	CcSEcCtD
Amsacrine—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000419	0.00181	CcSEcCtD
Amsacrine—ABCB1—thyroid gland—thyroid cancer	0.000418	0.0149	CbGeAlD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000415	0.00613	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—HPGD—thyroid cancer	0.000409	0.00604	CbGpPWpGaD
Amsacrine—Dizziness—Sorafenib—thyroid cancer	0.000409	0.00177	CcSEcCtD
Amsacrine—Mood swings—Doxorubicin—thyroid cancer	0.000408	0.00176	CcSEcCtD
Amsacrine—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000403	0.00174	CcSEcCtD
Amsacrine—Dysphagia—Epirubicin—thyroid cancer	0.000402	0.00174	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—CDK1—thyroid cancer	0.0004	0.00591	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.000398	0.00587	CbGpPWpGaD
Amsacrine—Vomiting—Sorafenib—thyroid cancer	0.000393	0.0017	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—PTEN—thyroid cancer	0.000393	0.00579	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—PCM1—thyroid cancer	0.000393	0.00579	CbGpPWpGaD
Amsacrine—Rash—Sorafenib—thyroid cancer	0.00039	0.00169	CcSEcCtD
Amsacrine—Dermatitis—Sorafenib—thyroid cancer	0.00039	0.00168	CcSEcCtD
Amsacrine—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000388	0.00168	CcSEcCtD
Amsacrine—Headache—Sorafenib—thyroid cancer	0.000388	0.00168	CcSEcCtD
Amsacrine—Pancytopenia—Epirubicin—thyroid cancer	0.000382	0.00165	CcSEcCtD
Amsacrine—Dysphagia—Doxorubicin—thyroid cancer	0.000372	0.00161	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—RXRA—thyroid cancer	0.000372	0.00548	CbGpPWpGaD
Amsacrine—ABCB1—head—thyroid cancer	0.000371	0.0132	CbGeAlD
Amsacrine—Nausea—Sorafenib—thyroid cancer	0.000367	0.00159	CcSEcCtD
Amsacrine—Weight increased—Epirubicin—thyroid cancer	0.000366	0.00158	CcSEcCtD
Amsacrine—NCOA3—Androgen receptor signaling pathway—AKT1—thyroid cancer	0.000365	0.00539	CbGpPWpGaD
Amsacrine—Weight decreased—Epirubicin—thyroid cancer	0.000364	0.00157	CcSEcCtD
Amsacrine—Infestation NOS—Epirubicin—thyroid cancer	0.000358	0.00155	CcSEcCtD
Amsacrine—Infestation—Epirubicin—thyroid cancer	0.000358	0.00155	CcSEcCtD
Amsacrine—Pancytopenia—Doxorubicin—thyroid cancer	0.000353	0.00153	CcSEcCtD
Amsacrine—Renal failure—Epirubicin—thyroid cancer	0.000352	0.00152	CcSEcCtD
Amsacrine—Jaundice—Epirubicin—thyroid cancer	0.000349	0.00151	CcSEcCtD
Amsacrine—Stomatitis—Epirubicin—thyroid cancer	0.000349	0.00151	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000348	0.00514	CbGpPWpGaD
Amsacrine—Haematuria—Epirubicin—thyroid cancer	0.000342	0.00148	CcSEcCtD
Amsacrine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000339	0.00147	CcSEcCtD
Amsacrine—Weight increased—Doxorubicin—thyroid cancer	0.000339	0.00146	CcSEcCtD
Amsacrine—Weight decreased—Doxorubicin—thyroid cancer	0.000337	0.00145	CcSEcCtD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000335	0.00494	CbGpPWpGaD
Amsacrine—Agranulocytosis—Epirubicin—thyroid cancer	0.000335	0.00145	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000332	0.0049	CbGpPWpGaD
Amsacrine—Infestation NOS—Doxorubicin—thyroid cancer	0.000332	0.00143	CcSEcCtD
Amsacrine—Infestation—Doxorubicin—thyroid cancer	0.000332	0.00143	CcSEcCtD
Amsacrine—Bradycardia—Epirubicin—thyroid cancer	0.000328	0.00142	CcSEcCtD
Amsacrine—Renal failure—Doxorubicin—thyroid cancer	0.000326	0.00141	CcSEcCtD
Amsacrine—Haemoglobin—Epirubicin—thyroid cancer	0.000323	0.0014	CcSEcCtD
Amsacrine—Stomatitis—Doxorubicin—thyroid cancer	0.000323	0.0014	CcSEcCtD
Amsacrine—Jaundice—Doxorubicin—thyroid cancer	0.000323	0.0014	CcSEcCtD
Amsacrine—Hepatitis—Epirubicin—thyroid cancer	0.000322	0.00139	CcSEcCtD
Amsacrine—Haemorrhage—Epirubicin—thyroid cancer	0.000322	0.00139	CcSEcCtD
Amsacrine—Hypoaesthesia—Epirubicin—thyroid cancer	0.00032	0.00138	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000319	0.00471	CbGpPWpGaD
Amsacrine—Urinary tract disorder—Epirubicin—thyroid cancer	0.000318	0.00137	CcSEcCtD
Amsacrine—Haematuria—Doxorubicin—thyroid cancer	0.000316	0.00137	CcSEcCtD
Amsacrine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000316	0.00137	CcSEcCtD
Amsacrine—Urethral disorder—Epirubicin—thyroid cancer	0.000315	0.00136	CcSEcCtD
Amsacrine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000314	0.00136	CcSEcCtD
Amsacrine—Agranulocytosis—Doxorubicin—thyroid cancer	0.00031	0.00134	CcSEcCtD
Amsacrine—Bradycardia—Doxorubicin—thyroid cancer	0.000303	0.00131	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—KRAS—thyroid cancer	0.000302	0.00445	CbGpPWpGaD
Amsacrine—Haemoglobin—Doxorubicin—thyroid cancer	0.000299	0.00129	CcSEcCtD
Amsacrine—Cardiac disorder—Epirubicin—thyroid cancer	0.000299	0.00129	CcSEcCtD
Amsacrine—Hepatitis—Doxorubicin—thyroid cancer	0.000298	0.00129	CcSEcCtD
Amsacrine—Haemorrhage—Doxorubicin—thyroid cancer	0.000298	0.00129	CcSEcCtD
Amsacrine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000296	0.00128	CcSEcCtD
Amsacrine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000294	0.00127	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000294	0.00433	CbGpPWpGaD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000293	0.00433	CbGpPWpGaD
Amsacrine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000293	0.00126	CcSEcCtD
Amsacrine—Angiopathy—Epirubicin—thyroid cancer	0.000292	0.00126	CcSEcCtD
Amsacrine—Urethral disorder—Doxorubicin—thyroid cancer	0.000292	0.00126	CcSEcCtD
Amsacrine—Mediastinal disorder—Epirubicin—thyroid cancer	0.00029	0.00125	CcSEcCtD
Amsacrine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000288	0.00425	CbGpPWpGaD
Amsacrine—Arrhythmia—Epirubicin—thyroid cancer	0.000287	0.00124	CcSEcCtD
Amsacrine—Alopecia—Epirubicin—thyroid cancer	0.000284	0.00123	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000284	0.00418	CbGpPWpGaD
Amsacrine—Mental disorder—Epirubicin—thyroid cancer	0.000282	0.00122	CcSEcCtD
Amsacrine—Malnutrition—Epirubicin—thyroid cancer	0.00028	0.00121	CcSEcCtD
Amsacrine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000276	0.00119	CcSEcCtD
Amsacrine—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000273	0.00403	CbGpPWpGaD
Amsacrine—Angiopathy—Doxorubicin—thyroid cancer	0.00027	0.00117	CcSEcCtD
Amsacrine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000268	0.00116	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000268	0.00396	CbGpPWpGaD
Amsacrine—Arrhythmia—Doxorubicin—thyroid cancer	0.000266	0.00115	CcSEcCtD
Amsacrine—Vision blurred—Epirubicin—thyroid cancer	0.000264	0.00114	CcSEcCtD
Amsacrine—Alopecia—Doxorubicin—thyroid cancer	0.000263	0.00114	CcSEcCtD
Amsacrine—Mental disorder—Doxorubicin—thyroid cancer	0.000261	0.00113	CcSEcCtD
Amsacrine—ABCB1—lymph node—thyroid cancer	0.00026	0.00925	CbGeAlD
Amsacrine—Malnutrition—Doxorubicin—thyroid cancer	0.000259	0.00112	CcSEcCtD
Amsacrine—Anaemia—Epirubicin—thyroid cancer	0.000259	0.00112	CcSEcCtD
Amsacrine—TOP2A—Daunorubicin—Epirubicin—thyroid cancer	0.000257	0.0304	CbGdCrCtD
Amsacrine—TOP2A—Idarubicin—Epirubicin—thyroid cancer	0.000257	0.0304	CbGdCrCtD
Amsacrine—TOP2A—Doxorubicin—Epirubicin—thyroid cancer	0.000257	0.0304	CbGdCrCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	0.000256	0.00378	CbGpPWpGaD
Amsacrine—Leukopenia—Epirubicin—thyroid cancer	0.000251	0.00108	CcSEcCtD
Amsacrine—Vision blurred—Doxorubicin—thyroid cancer	0.000244	0.00106	CcSEcCtD
Amsacrine—Convulsion—Epirubicin—thyroid cancer	0.000243	0.00105	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—TPR—thyroid cancer	0.00024	0.00354	CbGpPWpGaD
Amsacrine—Anaemia—Doxorubicin—thyroid cancer	0.00024	0.00104	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000239	0.00353	CbGpPWpGaD
Amsacrine—TOP2A—Idarubicin—Doxorubicin—thyroid cancer	0.000238	0.0281	CbGdCrCtD
Amsacrine—TOP2A—Daunorubicin—Doxorubicin—thyroid cancer	0.000238	0.0281	CbGdCrCtD
Amsacrine—TOP2A—Epirubicin—Doxorubicin—thyroid cancer	0.000238	0.0281	CbGdCrCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000237	0.00102	CcSEcCtD
Amsacrine—NCOA3—Metabolism—TPR—thyroid cancer	0.000235	0.00347	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—PPARG—thyroid cancer	0.000235	0.00346	CbGpPWpGaD
Amsacrine—Leukopenia—Doxorubicin—thyroid cancer	0.000232	0.001	CcSEcCtD
Amsacrine—NCOA3—Metabolism—PRKAR1A—thyroid cancer	0.000231	0.00341	CbGpPWpGaD
Amsacrine—Confusional state—Epirubicin—thyroid cancer	0.000231	0.000996	CcSEcCtD
Amsacrine—Infection—Epirubicin—thyroid cancer	0.000227	0.000982	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	0.000226	0.00334	CbGpPWpGaD
Amsacrine—Convulsion—Doxorubicin—thyroid cancer	0.000225	0.000971	CcSEcCtD
Amsacrine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000224	0.000968	CcSEcCtD
Amsacrine—Tachycardia—Epirubicin—thyroid cancer	0.000223	0.000964	CcSEcCtD
Amsacrine—Skin disorder—Epirubicin—thyroid cancer	0.000222	0.00096	CcSEcCtD
Amsacrine—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000221	0.00327	CbGpPWpGaD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000219	0.000947	CcSEcCtD
Amsacrine—Anorexia—Epirubicin—thyroid cancer	0.000218	0.000942	CcSEcCtD
Amsacrine—Hypotension—Epirubicin—thyroid cancer	0.000214	0.000923	CcSEcCtD
Amsacrine—Confusional state—Doxorubicin—thyroid cancer	0.000213	0.000922	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—PPARG—thyroid cancer	0.000211	0.00312	CbGpPWpGaD
Amsacrine—Infection—Doxorubicin—thyroid cancer	0.00021	0.000908	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.00021	0.00309	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000208	0.00308	CbGpPWpGaD
Amsacrine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000207	0.000895	CcSEcCtD
Amsacrine—Tachycardia—Doxorubicin—thyroid cancer	0.000206	0.000892	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000206	0.00304	CbGpPWpGaD
Amsacrine—Skin disorder—Doxorubicin—thyroid cancer	0.000205	0.000888	CcSEcCtD
Amsacrine—Paraesthesia—Epirubicin—thyroid cancer	0.000205	0.000887	CcSEcCtD
Amsacrine—Dyspnoea—Epirubicin—thyroid cancer	0.000204	0.000881	CcSEcCtD
Amsacrine—Anorexia—Doxorubicin—thyroid cancer	0.000202	0.000872	CcSEcCtD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000199	0.00294	CbGpPWpGaD
Amsacrine—Decreased appetite—Epirubicin—thyroid cancer	0.000199	0.000859	CcSEcCtD
Amsacrine—Hypotension—Doxorubicin—thyroid cancer	0.000198	0.000854	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000197	0.000853	CcSEcCtD
Amsacrine—Fatigue—Epirubicin—thyroid cancer	0.000197	0.000852	CcSEcCtD
Amsacrine—Pain—Epirubicin—thyroid cancer	0.000196	0.000845	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000193	0.00285	CbGpPWpGaD
Amsacrine—Paraesthesia—Doxorubicin—thyroid cancer	0.00019	0.000821	CcSEcCtD
Amsacrine—Dyspnoea—Doxorubicin—thyroid cancer	0.000189	0.000815	CcSEcCtD
Amsacrine—Feeling abnormal—Epirubicin—thyroid cancer	0.000188	0.000814	CcSEcCtD
Amsacrine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000187	0.000808	CcSEcCtD
Amsacrine—Decreased appetite—Doxorubicin—thyroid cancer	0.000184	0.000795	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000183	0.000789	CcSEcCtD
Amsacrine—Fatigue—Doxorubicin—thyroid cancer	0.000182	0.000788	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000182	0.00268	CbGpPWpGaD
Amsacrine—Urticaria—Epirubicin—thyroid cancer	0.000182	0.000785	CcSEcCtD
Amsacrine—Pain—Doxorubicin—thyroid cancer	0.000181	0.000782	CcSEcCtD
Amsacrine—Body temperature increased—Epirubicin—thyroid cancer	0.000181	0.000781	CcSEcCtD
Amsacrine—Abdominal pain—Epirubicin—thyroid cancer	0.000181	0.000781	CcSEcCtD
Amsacrine—NCOA3—Metabolism—SLC5A5—thyroid cancer	0.000176	0.0026	CbGpPWpGaD
Amsacrine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000174	0.000753	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000173	0.00255	CbGpPWpGaD
Amsacrine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000173	0.000748	CcSEcCtD
Amsacrine—Hypersensitivity—Epirubicin—thyroid cancer	0.000168	0.000728	CcSEcCtD
Amsacrine—Urticaria—Doxorubicin—thyroid cancer	0.000168	0.000726	CcSEcCtD
Amsacrine—Body temperature increased—Doxorubicin—thyroid cancer	0.000167	0.000723	CcSEcCtD
Amsacrine—Abdominal pain—Doxorubicin—thyroid cancer	0.000167	0.000723	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000165	0.00243	CbGpPWpGaD
Amsacrine—Asthenia—Epirubicin—thyroid cancer	0.000164	0.000709	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—CDK1—thyroid cancer	0.000162	0.0024	CbGpPWpGaD
Amsacrine—Diarrhoea—Epirubicin—thyroid cancer	0.000156	0.000676	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000156	0.00231	CbGpPWpGaD
Amsacrine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000156	0.000674	CcSEcCtD
Amsacrine—KCNH2—Neuronal System—BRAF—thyroid cancer	0.000153	0.00225	CbGpPWpGaD
Amsacrine—Asthenia—Doxorubicin—thyroid cancer	0.000152	0.000656	CcSEcCtD
Amsacrine—Dizziness—Epirubicin—thyroid cancer	0.000151	0.000653	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000151	0.00223	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—RXRA—thyroid cancer	0.000148	0.00218	CbGpPWpGaD
Amsacrine—Vomiting—Epirubicin—thyroid cancer	0.000145	0.000628	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—PTEN—thyroid cancer	0.000145	0.00214	CbGpPWpGaD
Amsacrine—Diarrhoea—Doxorubicin—thyroid cancer	0.000145	0.000626	CcSEcCtD
Amsacrine—Rash—Epirubicin—thyroid cancer	0.000144	0.000623	CcSEcCtD
Amsacrine—Dermatitis—Epirubicin—thyroid cancer	0.000144	0.000623	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000144	0.00212	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—NRAS—thyroid cancer	0.000144	0.00212	CbGpPWpGaD
Amsacrine—Headache—Epirubicin—thyroid cancer	0.000143	0.000619	CcSEcCtD
Amsacrine—Dizziness—Doxorubicin—thyroid cancer	0.00014	0.000605	CcSEcCtD
Amsacrine—Nausea—Epirubicin—thyroid cancer	0.000136	0.000587	CcSEcCtD
Amsacrine—Vomiting—Doxorubicin—thyroid cancer	0.000135	0.000581	CcSEcCtD
Amsacrine—Rash—Doxorubicin—thyroid cancer	0.000133	0.000577	CcSEcCtD
Amsacrine—Dermatitis—Doxorubicin—thyroid cancer	0.000133	0.000576	CcSEcCtD
Amsacrine—Headache—Doxorubicin—thyroid cancer	0.000133	0.000573	CcSEcCtD
Amsacrine—Nausea—Doxorubicin—thyroid cancer	0.000126	0.000543	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—KRAS—thyroid cancer	0.000124	0.00182	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000118	0.00173	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TERT—thyroid cancer	0.000117	0.00173	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000116	0.00171	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000115	0.00169	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—HRAS—thyroid cancer	0.000105	0.00155	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000103	0.00152	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—TP53—thyroid cancer	9.89e-05	0.00146	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PPARG—thyroid cancer	9.33e-05	0.00138	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—AKT1—thyroid cancer	9.28e-05	0.00137	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—MINPP1—thyroid cancer	9.17e-05	0.00135	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	8.7e-05	0.00128	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—MINPP1—thyroid cancer	8.64e-05	0.00127	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NDUFA13—thyroid cancer	7.79e-05	0.00115	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CCND1—thyroid cancer	7.57e-05	0.00112	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	7.34e-05	0.00108	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PTGS2—thyroid cancer	7.34e-05	0.00108	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CHST14—thyroid cancer	7.33e-05	0.00108	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	7.24e-05	0.00107	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	7.24e-05	0.00107	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.13e-05	0.00105	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—HRAS—thyroid cancer	7.03e-05	0.00104	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CHST14—thyroid cancer	6.9e-05	0.00102	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CCND1—thyroid cancer	6.77e-05	0.000999	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	6.7e-05	0.000989	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PTEN—thyroid cancer	6.4e-05	0.000944	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—HPGD—thyroid cancer	5.91e-05	0.000871	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	5.7e-05	0.000841	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—HPGD—thyroid cancer	5.57e-05	0.000821	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.42e-05	0.0008	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	5.15e-05	0.00076	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	4.97e-05	0.000733	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.56e-05	0.000672	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TP53—thyroid cancer	4.46e-05	0.000658	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.82e-05	0.000563	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—AKT1—thyroid cancer	3.69e-05	0.000544	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—TPR—thyroid cancer	3.39e-05	0.0005	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.39e-05	0.0005	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PRKAR1A—thyroid cancer	3.34e-05	0.000492	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—TPR—thyroid cancer	3.2e-05	0.000472	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	3.14e-05	0.000464	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.86e-05	0.000423	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—SLC5A5—thyroid cancer	2.54e-05	0.000375	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.39e-05	0.000353	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—RXRA—thyroid cancer	2.13e-05	0.000315	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—RXRA—thyroid cancer	2.01e-05	0.000297	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PPARG—thyroid cancer	1.35e-05	0.000199	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PPARG—thyroid cancer	1.27e-05	0.000187	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PTGS2—thyroid cancer	1.06e-05	0.000156	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PTGS2—thyroid cancer	9.99e-06	0.000147	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PTEN—thyroid cancer	9.24e-06	0.000136	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PTEN—thyroid cancer	8.71e-06	0.000128	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—AKT1—thyroid cancer	5.33e-06	7.86e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—AKT1—thyroid cancer	5.02e-06	7.4e-05	CbGpPWpGaD
